Porosome Therapeutics, Inc. (https://www.porosome.com), the holding company of Porosome.AI, “owns” the entire Porosome space. Using cryo-EM, associated molecular and biochemical approaches and AI, Porosome.AI maps the atomic structure of the porosome. It thus allows precision identification and targeting of porosome proteins and the engineering of peptide and small molecule drugs to modulate secretory disorders thereby treating the resulting disease. Porosome.AI has already discovered several small molecule drug candidates deemed safe by the FDA. Porosome.AI is transformative because it enables both the molecular-level understanding of the porosome nanomachine and its use as a platform for the design and development of novel drugs and therapies.